EVLO - Evelo Biosciences GAAP EPS of -$0.28 in-line November, 15 2022 08:47 AM Evelo Biosciences Inc. Evelo Biosciences press release ( NASDAQ: EVLO ): Q3 GAAP EPS of -$0.28 in-line. As of September 30, 2022, cash and cash equivalents were $69.1M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021 For further details see: Evelo Biosciences GAAP EPS of -$0.28 in-line